Talaris Therapeutics, Inc. (TALS) SEC Filing 8-K Material Event for the period ending Friday, October 29, 2021

Talaris Therapeutics, Inc.

CIK: 1827506 Ticker: TALS

View differences made from one to another to evaluate Talaris Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Talaris Therapeutics, Inc..


Assess how Talaris Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Talaris Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Material Contracts, Statements, Certifications & more

Talaris Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Ticker: TALS
CIK: 1827506
Form Type: 8-K Corporate News
Accession Number: 0001193125-21-316914
Submitted to the SEC: Tue Nov 02 2021 4:02:01 PM EST
Accepted by the SEC: Tue Nov 02 2021
Period: Friday, October 29, 2021
Industry: Biological Products No Disgnostic Substances
  1. Financial Exhibit
  2. Other Events

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: